ID CLB HC.PH.BIO.CLB
Develops drugs, biologics or cell and gene therapies with no approved product on the market (no revenue, or milestones only); such a developer is here, not in contract research.
Sector, group and industry above this class, as placed in the current release. The sector and the industry link to their companies.
Companies whose primary class this is. The sector and industry pages and the screener count them the same way.
| Company | Ticker | Country | Market cap | Filings |
|---|---|---|---|---|
| RECCE PHARMACEUTICALS LTD | RCE | Australia | — | 731 |
| EPIX Pharmaceuticals Inc Delisted | EPIX1 | United States of America | — | 725 |
| Rock Creek Pharmaceuticals Inc Delisted | RCPI | United States of America | — | 721 |
| InSite Vision Inc Delisted | INSV | United States of America | — | 720 |
| Five Prime Therapeutics Inc Delisted | FPRX | United States of America | — | 717 |
| Tetra Bio-Pharma Inc. Delisted | TBPMQ | Canada | — | 717 |
| LigaChem Biosciences Inc. | 141080 | South Korea | — | 714 |
| Humanigen Inc Delisted | HGEN | United States of America | — | 713 |
| Vion Pharmaceuticals Inc Delisted | VION | United States of America | — | 710 |
| GENAERA CORP Delisted | — | United States of America | — | 701 |
| RIBOMIC Inc. | 4591 | Japan | — | 700 |
| MICROMET, INC. Delisted | — | United States of America | — | 697 |
| GENVEC INC Delisted | — | United States of America | — | 696 |
| Maxygen Inc Delisted | MAXY | United States of America | — | 695 |
| NEUROTECH INTERNATIONAL LIMITED | NTI | Australia | — | 695 |
| AMPLIA THERAPEUTICS LIMITED | ATX | Australia | — | 693 |
| Chiome Bioscience Inc. | 4583 | Japan | — | 693 |
| PHARMACOPEIA INC Delisted | — | United States of America | — | 687 |
| Anthera Pharmaceuticals Inc Delisted | — | United States of America | — | 686 |
| 台灣微脂體股份有限公司 Delisted | 4152 | Taiwan | — | 686 |
| 제넥셀 Delisted | 034660 | South Korea | — | 685 |
| IMV Inc. Delisted | IMV | Canada | — | 682 |
| SillaJen, Inc. | 215600 | South Korea | — | 678 |
| Syros Pharmaceuticals, Inc. Delisted | — | United States of America | — | 677 |
| NeuBase Therapeutics Inc Delisted | NBSE | United States of America | — | 670 |
| DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. | 688192 | China | — | 667 |
| BetterLife Pharma | BETR | Canada | — | 666 |
| EyeGene,Inc | 185490 | South Korea | — | 666 |
| OLIPASS CORPORATION | 244460 | South Korea | — | 662 |
| ToolGen Incorporated | 199800 | South Korea | — | 661 |
| MEDAREX INC Delisted | — | United States of America | — | 658 |
| Dicerna Pharmaceuticals Inc Delisted | DRNA | United States of America | — | 652 |
| Aptahem AB | APTA | Sweden | — | 649 |
| Double Bond Pharmaceutical International AB | DBP B | Sweden | — | 647 |
| ALPINE IMMUNE SCIENCES, INC. Delisted | — | United States of America | — | 639 |
| Bellerophon Therapeutics, Inc. Delisted | — | United States of America | — | 639 |
| Mologen AG Delisted | MGNK | Germany | — | 639 |
| Mezzion Pharma Co., Ltd. | 140410 | South Korea | — | 638 |
| Cell Genesys Inc Delisted | CEGE | United States of America | — | 637 |
| Tyme Technologies Inc Delisted | TYME | United States of America | — | 619 |
| Endocyte Inc Delisted | ECYT | United States of America | — | 618 |
| Devonian Health Group Inc | GSD | Canada | — | 617 |
| Inhibitex Inc Delisted | INHX | United States of America | — | 615 |
| TREX WIND-DOWN, INC. Delisted | — | United States of America | — | 614 |
| Genocea Biosciences Inc Delisted | GNCA | United States of America | — | 613 |
| Ampio Pharmaceuticals, Inc. Delisted | — | United States of America | — | 612 |
| Kidswell Bio Corporation | 4584 | Japan | — | 612 |
| Transgene Biotek Ltd. | 526139 | India | — | 612 |
| Scorpius Holdings, Inc. | HTBX | United States of America | — | 610 |
| PANACOS PHARMACEUTICALS, INC. Delisted | — | United States of America | — | 609 |
Other names for this activity, and where neighboring activities go instead.
preclinicaldrug developer
Research-led company whose approved medicines, which it discovered, are in one or two therapeutic areas; it moves to Branded Prescription Drugs only after two consecutive annual reports with approved products in three or more.
https://financialfilings.com/oics/CLB/
This page is keyed by the class ID CLB. IDs are assigned in v0.3 and freeze at v1.0; from then on an ID is never renamed or reused, and if the class moves in the tree, its ID and this URL stay the same.
Sign in or create a free account - no password needed.
By continuing, you agree to our Terms and Privacy Policy.